References
- Andén N. E., Butcher S., Corrodi H., Fuxe K., Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Europ. J. Pharm. 1970; 11
- Borgd O., Azarnoff D. L., Forshell O., Sj F., öqvist. Plasma protein binding of tricyclic antidepressants in man. Biochem. Pharmacol. 1969; 18
- Brown G. A., Boos G. I., Soudijn W. Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. Part II. Distribution, excretion and metabolism of haloperidol in Spraque-Dawley rats. Europ. J. Pharm. 1967; 1
- Chase T. Central monoamine metabolism in man. Arch. Neurol. 1973; 29
- Collste P., Karlsson E., Norlander B., Sievers J., Sj F., öqvist. Arytmiprofylax med prokaminamid: Inadekvat dosering. Läkartidningen 1972; 69
- Ernebo M., Agurell S., Jalling B., Bor L. O., éus. Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults. Europ. J. Clin. Pharmacol. 1971; 3
- Forsman A., Nyberg G., Mårtensson E., Öhman R. A gas chromatographic method for determining haloperidol. Arch. Pharmacol. 1974
- Kutt H., Wolk M., Scherman R., Mc F., Dowell. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964; 14
- Marcucci F., Airoldi L., Mussini E., Garattini S. A method for the gas chromatographic determination of butyrophenones. J. Chromatog. 1971; 59
- Notari R. Biopharmaceutics and pharmacokinetics. Marcel Dekker Inc., New York 1971
- Schou M., Bastrup P. C., Grof P., Angst J. Pharmacological and clinical problems of lithium prophylaxis. Brit. J. Psychiat 1970; 116
- Sjökvist F., Alexandersson B., Åsberg M., Bertilsson L., Borg O.å, Hamberger B., Tuck D. Pharmacokinetics and biological effects of nortryptiline in man. Biological and pharmaceutical aspects of pharmacokinetics and therapeutics. Munks-gaard, Copenhagen 1971
- Smith T. Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. New Engl. J. Med. 1969; 281
- Soudijn W., Van J., Wijngaarden, Allewijn F. Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. Part I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the wistar rat. Europ. J. Pharm. 1967; 1
- Vesell E., Passinanti T., Greene F., Page J. Genetic control of drug-metabolizing enzymes in man: Individual variability in the extent of allopurinol and nortryptiline inhibition of drug metabolism. Ann. N.Y. Acad. Sci. 1971; 179
- Zingales I. A. A gas chromatographic method for the determination of haloperidol in human plasma. J. Chromatog. 1971; 54